Pivotal readout
Alnylam's five-year HELIOS-B data favor starting vutrisiran early in ATTR-CM
Patients treated with Amvuttra throughout the extension had a 41% lower five-year risk of death or recurrent cardiovascular events than those who started roughly three years later. Those p-values were nominal, with no correction for multiple testing. A separate exploratory look at 48 patients found exercise capacity was preserved over two years compared with placebo.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.
